A phase III clinical study revealed that, compared to chemotherapy alone, the use of PD-1 inhibitors in conjunction with standard chemotherapy significantly improves the overall survival rate of patients with non-small cell lung cancer (52). Here, PDCD1 is linked to non-small cell lung carcinoma.